- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 10-K Annual report
- 10.4 Office Lease
- 12.1 Statement Re: Computation of Ratio of Earnings to Fixed Charges
- 21.1 Subsidiaries of the Registrant
- 23.1 Consent of Stonefield Josephson, Inc.
- 23.2 Consent of Marcum LLP
- 31.1 Certification of Chief Executive Officer Pursuant to Section 302
- 31.2 Certification of Chief Financial Officer Pursuant to Section 302
- 32 Certification of Chief Executive Officer and Chief Financial Officer
Exhibit 23.2
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT
We consent to the incorporation by reference in the Registration Statement of Cell Therapeutics, Inc. on Form S-3 (Nos. 333-108926, 333-134126, 333-149980, 333-149981, 333-152171, 333-157376, 333-160969, 333-163479, 333-161442 and 333-177506) and Form S-8 (Nos. 333-152168, 333-158260, 333-162955, 333-170044 and 333-178158) of our report which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, dated March 8, 2012 with respect to our audits of the consolidated financial statements of Cell Therapeutics as of December 31, 2011 and 2010, and for the years then ended and our report dated March 8, 2012 with respect to our audit of the effectiveness of internal control over financial reporting of Cell Therapeutics, Inc. as of December 31, 2011, which reports are included in this Annual Report on Form 10-K of Cell Therapeutics, Inc. for the year ended December 31, 2011.
/s/ MarcumLLP
San Francisco, California
March 8, 2012